Results 61 to 70 of about 616,871 (170)

Identification of novel Menin-MLL interaction inhibitors targeting leukemia using in-silico virtual screening and structure-based drug design approaches

Journal of Genetic Engineering and Biotechnology
Leukemogenesis fundamentally depends on the interaction between Menin and MLL1 fusion proteins, especially in the context of aggressive mixed-lineage leukemia (MLL)-rearranged subtypes.
Amany I. Almars, Shahad W. Kattan
doaj   +1 more source

MLL oncoprotein levels influence leukemia lineage identities

Nature Communications
Chromosomal translocations involving the mixed-lineage leukemia (MLL) locus generate potent oncogenic fusion proteins (oncoproteins) that disrupt regulation of developmental gene expression.
Derek H. Janssens, Melodie Duran, Dominik J. Otto, Weifang Wu, Yiling Xu, Danielle Kirkey, Charles G. Mullighan, Joanna S. Yi, Soheil Meshinchi, Jay F. Sarthy, Kami Ahmad, Steven Henikoff   +11 more
doaj   +1 more source

Research Progress on the KMT2A-AFF3 Fusion Gene in Childhood Acute Lymphoblastic Leukemia: Mechanisms, Clinical Implications, and Therapeutic Strategies

Current Issues in Molecular Biology
KMT2A-rearranged (KMT2A-r) acute lymphoblastic leukemia (ALL), particularly in infants, represents one of the most aggressive pediatric hematological malignancies with a historically dismal prognosis.
Yawei Zhang, Juan Liang
doaj   +1 more source

Epigenetic regulation of noncanonical menin targets modulates menin inhibitor response in acute myeloid leukemia

Blood
Abstract Menin inhibitors that disrupt the menin-MLL interaction hold promise for treating specific acute myeloid leukemia (AML) subtypes, including those with KMT2A rearrangements (KMT2A-r), yet resistance remains a challenge. Here, through systematic chromatin-focused CRISPR screens, along with genetic, epigenetic,
Xinyue Zhou, Lixia Zhang, Sajesan Aryal, Virginia Veasey, Amanda Tajik, Cecilia Restelli, Steven Moreira, Pengcheng Zhang, Yanfeng Zhang, Kristin J. Hope, Yang Zhou, Changde Cheng, Ravi Bhatia, Rui Lu   +13 more
openaire   +2 more sources

Glucose-Mediated Repression of Menin Promotes Pancreatic β-Cell Proliferation

, 2012
Menin, encoded by the Men1 gene, is responsible for β-cell tumor formation in patients with multiple endocrine neoplasia type 1. Recently, menin has been proven to negatively regulate β-cell proliferation during pregnancy.
Fengying Li, Yun Liu, Wenyi Li, Guang Ning, Cuiping Zhang, Ling Wu, Hongmei Long, Qidi Wang, Hongli Zhang, Min Luo, Xiao Wang, Guo Li, Xiaoying Li   +12 more
core   +1 more source

Mario Menin. camicia nera futurista e primo battaglista del mondo

Mario Menin : camicia nera futurista e primo battaglista del mondo / (presentazione di Filippo Tommaso Marinetti e Luigi Scrivo). - Roma : Edizioni futuriste di poesia, stampa 1941 Dedica manoscritta dell\u27autore: A Bodrero Emilio / con ammirazione ...
Menin, Mario
core  

Menin maintains enhancer-promoter interactions in a leukemia-specific manner [PDF]

Inhibition of the protein-protein interaction between Mixed Lineage Leukemia (MLL/KMT2A) protein and the adapter protein Menin is a promising therapy for both high-risk MLL-rearranged and NPM1-mutant (NPM1c) acute leukemias.
Kessler, Benedikt, Vendrell-Monell, Iolanda, Hamley, Joseph, Konopleva, Marina, Smith, Alastair, Davies, James, Crump, Nicholas T, Denny, Nicholas, Sharlandjieva, Vassilena, Lassen, Frederik Heymann, Milne, Thomas, Stam, Ronald W, Chahrour, Catherine, Damianou, Andreas, Roy, Anindita, Hester, Svenja   +15 more
core   +1 more source

Upfront menin-inhibitor resistance in multiply pretreated leukemias

Experimental Hematology
Inhibitors of the menin-KMT2A interaction are promising agents for the treatment of KMT2A-rearranged leukemias. We evaluated menin inhibition in patient-derived xenografts of KMT2A-rearranged leukemias with high-risk features. Three acute myeloid leukemias with high-risk fusion partners (mixed-lineage leukemia-10 [MLLT10] and mixed-lineage leukemia-4 ...
Leila Mahdavi, Fatemeh Alikarami, Haley Goodrow, Alexandra Lenard, Simone S. Riedel, Clara Libbrecht, Isabel Bowser, Sarah K. Tasian, Catherine D. Falkenstein, Bryan Manning, Sarah Skuli, Martin P. Carroll, Gerald Wertheim, Sheng F. Cai, Gerard McGeehan, Sixiang Yu, Junwei Shi, Hongbo M. Xie, Kathrin M. Bernt   +18 more
openaire   +2 more sources

Targeted and epigenetic therapies for acute myeloid leukemia treatment

Discover Oncology
This article provides a comprehensive overview of targeted and epigenetic therapies for acute myeloid leukemia (AML), highlighting their role in advancing treatment strategies.
Marzieh Shokoohi, Mobin Ghaderi, Milad Mokarami, Homaira Arian, Sara Mohammadnabi, Arastoo Farokhi   +5 more
doaj   +1 more source

Synergistic targeting of KMT2A-rearranged AML with combined LSD1 and menin inhibitors

KMT2A-rearranged (KMT2Ar) acute myeloid leukemia (AML) is a high-risk subtype of AML associated with poor prognosis and frequent relapse. Standard therapies often fail to achieve durable remission, underscoring the urgent need for novel treatments. Menin
Beckedorff, Felipe, Shiekhattar, Ramin, Totiger, Tulasigeri, Huang, Hsuan-Ting, Mas Martin, Gloria, Bilbao, Daniel, Mookhtiar, Adnan, Karaca, Efe, Tayari, Mina, Taylor, Justin, Watts, Justin, Kingham, Anna Lesley   +11 more
core   +1 more source